

**Last Menstrual Period:**


**Ordering Provider:**  
Rn Labs

**DOB:** 1962-09-18  
**Age:** 59  
**Sex:** Female



**Collection Times:**  
2022-02-06 07:50AM (S)  
2022-02-06 08:20AM (S)  
2022-02-06 08:50AM (S)  
2022-02-06 04:20PM (S)  
2022-02-06 09:13PM (S)  
2022-02-06 07:50AM (U)  
2022-02-06 10:30AM (U)  
2022-02-06 04:20PM (U)  
2022-02-06 09:10PM (U)

## Hormone Testing Summary


### Key (how to read the results):




### Sex Hormones See Pages 2 and 3 for a thorough breakdown of sex hormone metabolites



Progesterone Serum Equivalent is a calculated value based on urine pregnanediol.




### Adrenal Hormones See pages 4 and 5 for a more complete breakdown of adrenal hormones




Free cortisol best reflects tissue levels. Metabolized cortisol best reflects total cortisol production.

### Total DHEA Production


| Age   | Range     |
|-------|-----------|
| 20-39 | 1300-3000 |
| 40-59 | 750-2000  |
| >60   | 500-1200  |



Total DHEA Production  
(DHEAS + Etiocholanolone + Androsterone)



cortisol  
metabolism



The following videos (which can also be found on the website under the listed names along with others) may aid your understanding:

[DUTCH Plus Overview](#) (quick overview) [Estrogen Tutorial](#) [Female Androgen Tutorial](#) [Cortisol/CAR Tutorial](#)

**PLEASE BE SURE TO READ BELOW FOR ANY SPECIFIC LAB COMMENTS. More detailed comments can be found on page 7.**

- Note that the Progesterone Serum Equivalent is not a valid concept when patients are taking oral or sublingual progesterone. Swallowed progesterone creates very high levels of the metabolites measured and these do not necessarily parallel serum progesterone.  
- The patient collected an "Insomnia" salivary sample in the middle of the night. The cortisol result for this sample was 1.65ng/mL (expected range 0-0.9). Please see page 4 for cortisol and cortisone results for this sample.  
The Cortisol Awakening Response (CAR) actually showed a decrease in this case. Normal results show an increase of 50-160%. See page 5.

**Sex Hormones and Metabolites**
**Last Menstrual Period:**
**Ordering Provider:**

Rn Labs

**DOB:** 1962-09-18

**Age:** 59

**Sex:** Female

**Collection Times:**


 2022-02-06 07:50AM (S)  
 2022-02-06 08:20AM (S)  
 2022-02-06 08:50AM (S)  
 2022-02-06 04:20PM (S)  
 2022-02-06 09:13PM (S)  
 2022-02-06 07:50AM (U)  
 2022-02-06 10:30AM (U)  
 2022-02-06 04:20PM (U)  
 2022-02-06 09:10PM (U)

| Test                              |                         | Result | Units | Luteal*    | Postmenopausal |
|-----------------------------------|-------------------------|--------|-------|------------|----------------|
| Progesterone Metabolites (Urine)  |                         |        |       | Range      | Range          |
| b-Pregnanediol                    | Below luteal range      | 466.0  | ng/mg | 600 - 2000 | 60-200         |
| a-Pregnanediol                    | Below luteal range      | 80.4   | ng/mg | 200 - 740  | 15-50          |
| Estrogens and Metabolites (Urine) |                         |        |       |            |                |
| Estrone(E1)                       | Below luteal range      | 6.1    | ng/mg | 12 - 26    | 1.0-7.0        |
| Estradiol(E2)                     | Below luteal range      | 0.59   | ng/mg | 1.8 - 4.5  | 0.2-0.7        |
| Estriol(E3)                       | Above luteal range      | 28.0   | ng/mg | 5 - 18     | 0.6-4.0        |
| 2-OH-E1                           | Within luteal range     | 9.24   | ng/mg | 5.1 - 13.1 | 0.3-2.0        |
| 4-OH-E1                           | Within luteal range     | 0.69   | ng/mg | 0 - 1.8    | 0-0.3          |
| 16-OH-E1                          | Within luteal range     | 1.21   | ng/mg | 0.7 - 2.6  | 0.2-0.6        |
| 2-Methoxy-E1                      | Within luteal range     | 4.46   | ng/mg | 2.5 - 6.5  | 0.3-1.4        |
| 2-OH-E2                           | Within luteal range     | 0.56   | ng/mg | 0 - 1.2    | 0-0.3          |
| 4-OH-E2                           | Low end of luteal range | 0.09   | ng/mg | 0 - 0.5    | 0-0.1          |
| Total Estrogen                    | Within range            | 51.0   | ng/mg | 35 - 70    | 4.0-15         |
| Androgens and Metabolites (Urine) |                         |        |       |            |                |
| DHEA-S                            | Within range            | 180.3  | ng/mg | 20 - 750   |                |
| Androsterone                      | Low end of range        | 430.7  | ng/mg | 200 - 1650 |                |
| Etiocholanolone                   | Within range            | 558.7  | ng/mg | 200 - 1000 |                |
| Testosterone                      | Within range            | 5.05   | ng/mg | 2.3 - 14   |                |
| 5a-DHT                            | Within range            | 3.6    | ng/mg | 0 - 6.6    |                |
| 5a-Androstenediol                 | Within range            | 15.1   | ng/mg | 6 - 30     |                |
| 5b-Androstenediol                 | Low end of range        | 29.1   | ng/mg | 20 - 75    |                |
| Epi-Testosterone                  | Below range             | 0.7    | ng/mg | 2.3 - 14   |                |

\*the Luteal Range is the premenopausal range. When patients are taking oral progesterone this range for progesterone metabolites is not luteal and reflects the higher levels expected when patients take oral progesterone. This test is intended to be taken in the luteal phase of the menstrual cycle (days 19-22 of a 28 day cycle) for premenopausal women. The ranges in the table below may be used when samples are taken during the first few days (follicular) of the cycle, during ovulation (days 11-14) or when patients are on oral progesterone. See the following pages for age-dependent ranges for androgen metabolites.

| Additional Normal Ranges | Follicular | Ovulatory | Oral Pg (100mg) |
|--------------------------|------------|-----------|-----------------|
| b-Pregnanediol           | 100-300    | 100-300   | 2000-9000       |
| a-Pregnanediol           | 25-100     | 25-100    | 580-3000        |
| Estrone (E1)             | 4.0-12.0   | 22-68     | N/A             |
| Estradiol (E2)           | 1.0-2.0    | 4.0-12.0  | N/A             |

Hormone metabolite results from the previous page are presented here as they are found in the steroid cascade. See the Provider Comments for more information on how to read the results.




**Adrenal**
**Last Menstrual Period:**
**Ordering Provider:**  
 Rn Labs

**DOB:** 1962-09-18  
**Age:** 59  
**Sex:** Female

**Collection Times:**  
 2022-02-06 07:50AM (S)  
 2022-02-06 08:20AM (S)  
 2022-02-06 08:50AM (S)  
 2022-02-06 04:20PM (S)  
 2022-02-06 09:13PM (S)  
 2022-02-06 02:50AM (S\*)  
 2022-02-06 07:50AM (U)  
 2022-02-06 10:30AM (U)  
 2022-02-06 04:20PM (U)  
 2022-02-06 09:10PM (U)

| Category  | Test                           | Result           | Units  | Normal Range      |
|---|--------------------------------|------------------|--------|-------------------|
| <b>Free Cortisol and Cortisone (Saliva)</b>       |                                |                  |        |                   |
|   | Saliva Cortisol - Waking (W)   | Within range     | 2.3    | ng/mL 1.6 - 4.6   |
|   | Saliva Cortisol - W+30 min.    | Below range      | 2.09   | ng/mL 3.7 - 8.2   |
|   | Saliva Cortisol - W+60 min.    | Below range      | 1.21   | ng/mL 2.3 - 5.3   |
|   | Saliva Cortisol - Afternoon    | Low end of range | 0.49   | ng/mL 0.4 - 1.5   |
|   | Saliva Cortisol - Night        | Within range     | 0.32   | ng/mL 0 - 0.9     |
|   | Saliva Cortisone - Waking (W)  | Low end of range | 7.01   | ng/mL 6.8 - 14.5  |
|   | Saliva Cortisone - W+30 min.   | Below range      | 7.66   | ng/mL 12.4 - 19.4 |
|   | Saliva Cortisone - W+60 min.   | Below range      | 6.23   | ng/mL 9.4 - 15.3  |
|   | Saliva Cortisone - Afternoon   | Low end of range | 2.56   | ng/mL 2 - 7.1     |
|   | Saliva Cortisone - Night       | Within range     | 1.49   | ng/mL 0 - 4.8     |
|   | Saliva Cortisol Total          | Below range      | 6.41   | ng/mL 9.6 - 19.3  |
|   | Saliva Cortisone Total         | Below range      | 24.95  | ng/mL 36 - 55     |
| <b>Creatinine (Urine)</b>                         |                                |                  |        |                   |
|   | Creatinine A (Waking)          | Within range     | 0.23   | mg/ml 0.2 - 2     |
|   | Creatinine B (Morning)         | Below range      | 0.16   | mg/ml 0.2 - 2     |
|   | Creatinine C (Afternoon)       | Within range     | 0.7    | mg/ml 0.2 - 2     |
|   | Creatinine D (Night)           | Within range     | 1.08   | mg/ml 0.2 - 2     |
| <b>Cortisol Metabolites and DHEA-S (Urine)</b>    |                                |                  |        |                   |
|   | a-Tetrahydrocortisol (a-THF)   | Below range      | 54.9   | ng/mg 75 - 370    |
|   | b-Tetrahydrocortisol (b-THF)   | Within range     | 2168.2 | ng/mg 1050 - 2500 |
|   | b-Tetrahydrocortisone (b-THE)  | Within range     | 2604.7 | ng/mg 1550 - 3800 |
|   | Metabolized Cortisol (THF+THE) | Within range     | 4827.8 | ng/mg 2750 - 6500 |
|   | DHEA-S                         | Within range     | 180.3  | ng/mg 20 - 750    |
| <b>Additional Cortisol and Cortisone (Saliva)</b> |                                |                  |        |                   |
|   | * Saliva Cortisol - Insomnia   | Above range      | 1.65   | ng/mL 0 - 0.9     |
|   | * Saliva Cortisone - Insomnia  | Above range      | 5.47   | ng/mL 0 - 4.8     |



- The patient submitted an Insomnia salivary sample. The cortisol result for this sample was 1.65ng/mL (expected range 0-0.9) The cortisone result for this sample was 5.5 ng/mL (expected range 0-4.8)

The Cortisol Awakening Response (CAR) is the rise in salivary cortisol between the waking sample and the sample collected 30 (as well as 60) minutes later. This "awakening response" is essentially a "mini stress test" and is a useful measurement in addition to the overall up-and-down (diurnal) pattern of free cortisol throughout the day. **This patient shows a waking cortisol of 2.30 and was actually lower at 2.09 after 30.0 minutes. This implies potential dysfunction in the HPA-axis or possibly improper collection.** Expected increases differ depending on the methods used. Preliminary research shows that 50-160% or 1.5-4.0ng/mL increases are common. These guidelines are considered research only. **This patient shows a salivary cortisol of 1.21 measured 60 minutes after waking. Generally this result is a little higher than the waking sample but is not in this case. To date, data suggests that expected results may be 0-70% higher, and this guideline is considered for research only.**

**Organic Acid Tests (OATs)**
**Ordering Provider:**

Rn Labs

**DOB:** 1962-09-18

**Age:** 59

**Sex:** Female

**Last Menstrual Period:**
**Collection Times:**

 2022-02-06 07:50AM (S)  
 2022-02-06 08:20AM (S)  
 2022-02-06 08:50AM (S)  
 2022-02-06 04:20PM (S)  
 2022-02-06 09:13PM (S)  
 2022-02-06 07:50AM (U)  
 2022-02-06 10:30AM (U)  
 2022-02-06 04:20PM (U)  
 2022-02-06 09:10PM (U)

| Category   | Test                 | Result           | Units | Normal Range     |
|--|----------------------|------------------|-------|------------------|
| <b>Nutritional Organic Acids</b>   |                      |                  |       |                  |
| Vitamin B12 Marker (may be deficient if high) - (Urine)                                  |                      |                  |       |                  |
|  | Methylmalonate (MMA) | Above range      | 2.7   | ug/mg 0 - 2.5    |
| Vitamin B6 Markers (may be deficient if high) - (Urine)                                  |                      |                  |       |                  |
|  | Xanthurenate         | Within range     | 0.75  | ug/mg 0.12 - 1.2 |
|  | Kynurenate           | Within range     | 3.5   | ug/mg 0.8 - 4.5  |
| Glutathione Marker (may be deficient if low or high) - (Urine)                           |                      |                  |       |                  |
|  | Pyroglutamate        | Above range      | 90.3  | ug/mg 28 - 58    |
| <b>Neurotransmitter Metabolites</b>  |                      |                  |       |                  |
| Dopamine Metabolite - (Urine)  |                      |                  |       |                  |
|  | Homovanillate (HVA)  | Within range     | 5.5   | ug/mg 3 - 11     |
| Norepinephrine/Epinephrine Metabolite - (Urine)  |                      |                  |       |                  |
|  | Vanilmandelate (VMA) | Low end of range | 2.7   | ug/mg 2.2 - 5.5  |
| Melatonin (*measured as 6-OH-Melatonin-Sulfate) - (Urine)                                |                      |                  |       |                  |
|  | Melatonin* (Waking)  | Low end of range | 21.8  | ng/mg 10 - 85    |
| Oxidative Stress / DNA Damage, measured as 8-Hydroxy-2-deoxyguanosine (8-OHdG) - (Urine) |                      |                  |       |                  |
|  | 8-OHdG (Waking)      | Within range     | 2.2   | ng/mg 0 - 5.2    |

# Clinical Support Overview

Thank you for choosing DUTCH for your functional endocrinology testing needs! We know you have many options to choose from when it comes to functional endocrinology evaluation, and we strive to offer the best value, the most up-to-date testing parameters and reference ranges, and the greatest clinical support to ensure the most accurate results.




Please take a moment to read through the Clinical Support Overview below. These comments are specific to the patient's lab results. They detail the most recent research pertaining to the hormone metabolites, treatment considerations, and follow-up recommendations. These comments are intended for educational purposes only. Specific treatment should be managed by a healthcare provider. To view the steroid pathway chart, click here [Steroid Pathway Chart](#)

## Alert comments:






## How to read the DUTCH report


This report is not intended to treat, cure or diagnose any specific diseases. The graphic dutch dials in this report are intended for quick and easy evaluation of which hormones are out of range. Results below the left star are shaded yellow and are below range (left). Results between the stars and shaded green are within the reference range (middle). Results beyond the second star and shaded red are above the reference range (right). Some of these hormones also change with age, and the age-dependent ranges provided should also be considered.



For female reproductive hormones, a purple band is present on the dutch dials. This band represents the expected levels (reference range) for postmenopausal (or non-cycling) women.



In a few places on the graphical pages, you will see fan-style gauges. For sex hormones, you will see one for the balance between 5a/5b metabolism as well as methylation. For adrenal hormones, you will see one to represent the balance between cortisol and cortisone metabolites. These indexes simply look at the ratio of hormones for a preference. An average or "normal" ratio between the two metabolites (or groups of metabolites) will give a result in the middle (as shown here). If the ratio between the metabolites measured is "low" the gauge will lean to the left and similarly to the right if the ratio is higher than normal.



## Patient or Sample Comments

Throughout the provider comments you may find some comments specific to your situation or results. These comments will be found in this section or within another section as appropriate. Comments in other sections that are specific to your case will be in **bold**.

**The patient reports no menstrual cycles.**

**The patient reports significant symptoms of estrogen deficiency.**

**The patient reports significant symptoms of androgen deficiency.**

**The patient reported significant fatigue in the afternoon/evening, but not in the morning.**

## Progesterone Metabolism

Progesterone is made predominately in the ovaries by the corpus luteum following the release of an egg. Progesterone metabolite levels will increase to the premenopausal luteal range (the range established as the green band between the two gold stars) only after the release of an egg. The level of progesterone metabolites seen on the DUTCH test can help determine if ovulation occurred 5-7 days prior to test collection.

The primary role of progesterone is to prepare the endometrium of the uterus for implantation. In addition, it may balance the effects of estrogen, it is a neurosteroid, it acts as a diuretic and raises basal body temperature.

We are measuring metabolites of progesterone 5b-pregnanediol and 5a-pregnanediol. 5b-pregnanediol has less activity in the body but does represent a larger percent of total progesterone metabolism overall. 5a-pregnanediol is often a metabolite of more interest, as it can cross the blood brain barrier and up-regulate GABA activity and is considered neuroprotective to the brain. In some women the 5a-pregnanediol is also the cause of PMDD and irritability due to issues with the GABA receptor's inability to adjust for sensitivity to fluctuating



neurosteroids (Dr Briden).

If progesterone levels are in the low or lower end of the luteal reference range compared to estrogen levels, women may experience symptoms such as PMS, menorrhagia, mastalgia, moodiness, anxiety, and/or insomnia.

The metabolites of progesterone are excreted in urine (not the progesterone itself). When ordering the DUTCH Complete and DUTCH Plus reports, you will see a Progesterone Serum Equivalent on the summary page 1. The urine metabolites of progesterone have been proven to correlate strongly to serum progesterone. The Progesterone Serum Equivalent is most accurate with values in the luteal range and becomes more approximate at very low numbers in the postmenopausal range. Cycling women with very high progesterone metabolites may also decrease the accuracy of the serum equivalent calculation.

NOTE: If progesterone is taken orally (also with sublingual), these metabolites are elevated from gut metabolism and results do NOT accurately reflect serum levels.

**The patient reported sublingual progesterone use. Results should be interpreted with care. Some of the progesterone taken will naturally be swallowed. This will allow first pass gut metabolism to greatly increase urine values as it creates a high number of metabolites. This means the results are a combination of actual progesterone in use coupled with those high metabolites numbers due to first-pass in the gut (not in use).**

**The reference range for progesterone metabolites with oral progesterone are listed on page 1 or 2. Since the amount of progesterone swallowed differs from one situation to the next, it is not practical to have sublingual progesterone ranges. Urine values in this situation have limited clinical utility. Serum equivalent values (given with DUTCH Complete on page 1) will be higher than reality when progesterone is taken sublingually.** This [video](#) may assist with understanding results in this situation.

### Estrogen Metabolism

As of 12.3.2021 we have discontinued 2-methoxy-E2. After careful consideration of measurements of both 2-methoxy-E2 as well as 4-methoxy-E1, we have determined that the relationship between 2-OH-E1 and 2-methoxy-E1 is the best way to determine methylation of catechol estrogen metabolites. Our decision reflects our commitment to focusing on the most reliable laboratory measurements when making clinical decisions.

When evaluating estrogen levels, it is important to assess the following:

- **The status (low, normal or high?) of estrogen production:**

Levels of the primary ovarian product, estradiol (the strongest estrogen), as well as "total estrogens" may be considered. For women not on HRT, consider the appropriate range (premenopausal or postmenopausal).

**The patient reports the use of sublingual estrogen. Some of the sublingual hormone will naturally be swallowed while it is being dissolved in the mouth. As a result, the part swallowed goes through first pass in the gut creating a higher number of metabolites not in use. Therefore, absolute levels of estrogen in use by the body are difficult to assess with sublingual hormones because the results are a combination of actual estrogen in use and metabolites created by swallowing part of the sublingual estrogen. If the patient is successful in taking the supplement without swallowing a significant fraction, the lab values are most useful. High results are likely the result of swallowing hormone, so confidence in these results is not as high as with other scenarios. If the patient skips the dose the day of the test, this will not be problematic, but the values may be somewhat of an underestimation since they would not represent the increase of hormone in the few hours following the supplementation.** This [video](#) may assist with understanding results in this situation.

- **Phase I Metabolism:**

Estrogen is metabolized (primarily by the liver) down three phase I pathways. The 2-OH pathway is considered the safest because of the anti-cancer properties of 2-OH metabolites. Conversely, the 4-OH pathway is considered the most genotoxic as its metabolites can create reactive products that damage DNA. The third pathway, 16-OH creates the most estrogenic of the metabolites (although still considerably less estrogenic than estradiol) - 16-OH-E1. If overall estrogen levels are high, production of 16-OH-E1 may exacerbate high estrogen symptoms. Similarly, a woman with very low levels of estrogens, may have less low estrogen symptoms if 16-OH metabolism is preferred. For example Armamento-Villareal showed that a higher 2-OH-E1/16-OH-E1 ratio correlated to bone loss (a low estrogen symptom). Estriol is thought of as a safer (weaker) estrogen metabolite, but it is important to remember that estriol is actually 16-OH-E2, so generally patients that make a lot of the

potentially protective/weak estriol may also make a lot of the estrogenic 16-OH-E1. When evaluating phase I metabolism, it may be important to look at the ratios of the three metabolites to see which pathways are preferred relative to one another. It may also be important to compare these metabolites to the levels of the parent hormones (E1, E2). If the ratios of the three metabolites are favorable but overall levels of metabolites are much lower than E1 and E2, this may imply sluggish phase I clearance of estrogens, which can contribute to high levels of E1 and E2. Similarly, patients with excessive phase I metabolism may have low E1 and E2 levels because of high rates of clearance (as opposed to simply not making a lot of estrogen). The pie chart will assist you in comparing the three pathway options of phase I metabolism compared to what is "normal." 2-OH metabolism can be increased by using products containing D.I.M. or I-3-C. These compounds are found (or created from) in cruciferous vegetables and are known for promoting this pathway.

**Phase I metabolism shows a preference for 2-OH metabolism, which is the protective pathway. The 4-OH and 16-OH pathways may be out of range despite this preference, so careful assessment is necessary. Products to increase 2-OH metabolism may be considered if E1 and E2 are elevated or if the 4-OH or 16-OH estrogens are high relative to 2-OH estrogens. Products that push the 2-OH pathway may also lower E1 and E2 levels, so keep this in mind when considering therapy.**

• **Methylation (part of phase II metabolism) of estrogens:**

After phase I metabolism, both 4-OH and 2-OH (not 16-OH) estrogens can be deactivated and eliminated by methylation. The methylation-activity index shows the patient's ratio of 2-Methoxy-E1 / 2-OH-E1 compared to what is expected. Low methylation can be caused by low levels of nutrients needed for methylation and/or genetic abnormalities (COMT, MTHFR). The COMT enzyme responsible for methylation requires magnesium and methyl donors. Deficiencies in folate or vitamin B6 or B12 can cause low levels of methyl donors. MTHFR genetic defects can make it more difficult for patients to make sufficient methyl donors. Genetic defects in COMT can make methylation poor even in the presence of adequate methyl donors.

### **Androgen Metabolism**

As of 12.3.2021 the reference range has been updated for 5a-androstanediol for female patients. This change represents improved analytical methods in migrating urine androgens from GC-MS/MS to LC-MS/MS. This improved method has necessitated a change to expected values for this one metabolite.

**Androgen Metabolites: DHEA**

DHEA and androstenedione are made almost exclusively by the adrenal gland (although a smaller amount is made in the ovaries for). These hormones appear in urine as DHEA-S (DHEA-Sulfate), androsterone and etiocholanolone.

DHEA peaks for men and women in their 20's and 30's, with a slow decline expected with age. DHEA mainly circulates throughout the body as DHEA-s, with interconversion to active DHEA as it reaches various tissues. DHEA is a weak androgen and will predominately convert to androstenedione, which will then convert to testosterone or estrogen. DHEA-s is made by sulfation, has a much longer half-life than DHEA and largely lacks a diurnal rhythm, which is why it is considered the best way to assess DHEA levels in the body. DHEA-s levels can be affected both by the total production as well as by the body's ability to sulfate DHEA.

The best way to assess the total production of DHEA is to add up these three metabolites. As DHEA production decreases quite significantly with age, we provide the age-dependent ranges. Adrenal DHEA serves as the main source of estrogen, progesterone and testosterone for post-menopausal women.

**The Total DHEA Production (page 1) was about 1,170ng/mg which is within the overall range and also within the age-dependent range for this patient. This implies that the adrenal glands are producing appropriate DHEA levels.**

• **Androgen Metabolites: Testosterone**

The DUTCH test measures the total of testosterone glucuronide and testosterone sulfate. These conjugates of testosterone are formed mostly from bioavailable testosterone that undergoes phase 2 metabolism to make it ready for urine excretion. Females make most of their DHEA in the adrenal gland and a fraction of that DHEA trickles down metabolically to testosterone. Testosterone is also made by the ovaries.

Testosterone glucuronide is mostly made by the UGT2B17 enzyme, which also makes the glucuronide forms of 5a-DHT and 5b-androstanediol. Genetic variants of this enzyme reduce the urinary levels of these hormones without affecting serum levels. The genetic variants of UGT2B17 vary in the population from 7-80% (variation dependent on genetic ancestry, with the highest rates in those of Asian descent). Heterozygous individuals show

milder reductions in urinary testosterone than homozygous. For this reason, low and very low levels of urinary testosterone should be confirmed with serum testing before treatment is applied. Serum testing can include free and total testosterone and SHBG.

Testosterone levels may be better understood by also considering its downstream metabolites (5 $\alpha$ -androstenediol, 5 $\beta$ -androstenediol). Technically, these metabolites can also be formed from DHEA metabolites without going through the testosterone pathway, but they generally tend to correlate with testosterone production.

Testosterone levels normally decline with age. Age dependent ranges are provided. Perimenopausal testosterone levels can transiently increase before declining again.

Epi-testosterone (epi-T) is made at about the same rate as testosterone but is not androgenic. In cases where testosterone in urine is low, such as with the UGT2B17 deletion discussed above, epi-T may be used as a proxy for testosterone production, meaning that higher epi-T levels may indicate that a low testosterone result is falsely low. After menopause, epi-T production is less reliable as a marker of testosterone production as epi-T levels drop more sharply than does testosterone during the menopause transition. While epi-T may have limited utility in some cases, it does enhance the picture when taking androgen metabolites together as a whole. Androgens, specifically DHT and testosterone, help to support skin, connective tissue, bone and muscle integrity and promote dopamine conversion in the brain, which can help with mood and libido.

**The testosterone level measured is 5.0ng/mg, which is within the overall normal range. If the patient complains of androgen imbalance symptoms, look at the metabolism and DHEA metabolites for further insight. Also, consider other causes. For example, hair loss, which can be androgenic, can also be caused by hypothyroidism, autoimmune disease, high stress or mineral deficiency. Acne, which can be androgenic, also has dietary triggers for some people, most commonly dairy and sugar.**

**The patient reports the use of sublingual testosterone. Some of the sublingual testosterone is naturally swallowed in the process of getting it dissolved. If the patient took the supplement the day of testing, results will be a combination of true sublingual testosterone that was absorbed as is in the use plus the first-pass metabolites from swallowed testosterone not in use. The metabolites created in first-pass will likely elevate testosterone above the true levels of actual systemic testosterone levels. If the supplement was skipped the day of testing, results likely reflect an underestimation (potentially significantly) of supplementation levels as testosterone will clear out rather rapidly. Sublingual testosterone can be very challenging to monitor with lab testing due to the speed of metabolism. If the patient is successful in taking the supplement without swallowing a significant fraction, the lab values are most useful. High results are likely the result of swallowing hormone, so confidence in these results is not as high as with other scenarios.**

When patients do not take testosterone, Epi-Testosterone is often at similar levels as testosterone. When testosterone is taken, Epi-testosterone usually decreases and may represent approximately how much endogenous testosterone is being made at this time (which is often suppressed when exogenous testosterone is taken). This [video](#) may assist with using epi-testosterone with TRT.


#### • **Androgen Metabolites: 5 $\alpha$ -reductase versus 5 $\beta$ reductase**

5 $\alpha$ -reductase converts testosterone into 5 $\alpha$ -DHT (DHT), which is even more potent (~3x) than testosterone. High levels of DHT can lead to symptoms associated with too much testosterone, including scalp hair loss, hirsutism, acne and oily skin.

Metabolites created down the 5 $\beta$ -pathway are significantly less androgenic than their 5 $\alpha$  counterparts.

The fan-style gauge below the hormones shows the 5 $\alpha$  or 5 $\beta$  preference based on etiocholanolone (5 $\beta$ ) and androsterone (5 $\alpha$ ) results. The gauge shows the relative ratio of 5 $\alpha$  to 5 $\beta$  products but does not express the absolute value of DHT or if 5 $\alpha$ -reductase inhibition is or is not indicated. Consider symptoms and look at the 5 $\alpha$ -DHT result if high androgen symptoms are a concern. Progesterone metabolites are also metabolized by 5 $\alpha$  and 5 $\beta$  enzymes and the balance between its two metabolites can be useful to confirm a 5 $\alpha$  or 5 $\beta$  preference overall (or tissue specific preference).

Example of how to read fan-style gauge for 5a-reductase activity:



**Neither testosterone or overall levels of DHEA are elevated, and 5a-metabolism is not elevated. This is consistent with the patient's lack of reporting androgen excess symptoms.**

When assessing androgens in women, it is important to consider DHEA and testosterone production, 5a-metabolism patterns as well as the patient symptoms. For example, a woman with higher levels of DHEA and testosterone will often have high androgen symptoms (facial hair, thinning scalp hair, etc.) exacerbated by 5a-metabolism.

If, on the other hand, she prefers 5b-metabolism she may not express high androgen symptoms in spite of higher levels of testosterone because 5b is the less androgenic pathway.

You will also see levels of epi-testosterone, which is not androgenic like testosterone. It happens to be produced in about the same concentrations as testosterone (this is an approximate relationship). This can be helpful when assessing the validity of urinary testosterone testing in an individual patient. If epi-testosterone is much higher than testosterone, serum testosterone assessment should be considered before initiating therapy for low testosterone. Epi-testosterone is suppressed when exogenous testosterone is given, which can serve as a proxy for assessing endogenous testosterone production which can be obscured by the exogenous hormone administration.

### DUTCH Adrenal

The HPA-Axis refers to the communication and interaction between the hypothalamus (H) and pituitary (P) in the brain down to the adrenal glands (A) that sit on top of your kidneys. When cortisol is needed in the body, the hypothalamus releases cortisol releasing hormone (CRH) and the pituitary responds by releasing adrenocorticotropic releasing hormone (ACTH), which is the signal to the adrenal gland to release cortisol, DHEA and DHEA-s. It is these adrenal hormones that are assessed on the DUTCH test to understand the patient's HPA axis.

The cortisol awakening response is a complex interaction between the HPA axis and the hippocampus, where ACTH normally surges right after waking leading to the day's highest levels of cortisol. This signal is considered by researchers to be separate from the regular circadian rhythm (the smooth transition from lower cortisol at night to modestly higher cortisol in the morning) and to reflect the person's anticipation of stress during the day, some psychosocial factors such as depression or anxiety and their metabolic state. The waking surge in cortisol helps with energy, focus, morning blood sugar and immune regulation.

As the day progresses, ACTH declines and subsequent cortisol decreases throughout the day, so it is low at night for sleep. This cycle starts over the next morning.

Free cortisol provides negative feedback to CRH & ACTH. When free cortisol is too low, ACTH will surge. ACTH will also surge when a physical or psychological stressor occurs.

Only a small fraction of cortisol is "free" and bioactive. The "free" cortisol is what the person feels in terms of energy and focus, and it is also what feeds back to the hypothalamus and pituitary gland for ACTH and cortisol regulation. The free cortisol daily pattern is very useful for understanding cortisol and its interaction with the patient's symptoms throughout the day. However, because only a fraction of the cortisol is bioactive, when considering treatments that affect the whole HPA axis, including DHEA, it is essential to measure metabolized

cortisol.

In urine, we can measure both the total metabolized cortisol (THF) and total metabolized cortisone (THE) excreted throughout the day. These two components better represent the total cortisol production from the adrenal glands than the free cortisol alone. Outside of the HPA axis, metabolism of cortisol occurs with the help of thyroid hormone in the liver. A significant amount of cortisol is also metabolized in adipose tissue.

To best determine total adrenal production of cortisol throughout the day it is important to measure both metabolized cortisol and free cortisol.

When evaluating cortisol levels, it is important to assess the following:

- **The daily pattern of free cortisol throughout the day, looking for low and high levels**

The patient is instructed to collect on a "typical" day because cortisol, as an acute response hormone, can vary from day to day if activities are very different. Abnormal results should be considered along with the patient's symptoms and any unusual occurrences of the day.

- **The sum of the free cortisol as an expression of the overall tissue cortisol exposure:**

This total of five free cortisol measurements is the best way to assess the total of free cortisol throughout the day, but do be aware that it is heavily weighted towards the morning production since three of five measurements are made within the first hour of the day.

- **The total level of cortisol metabolites:**

We call this calculation "Metabolized Cortisol" which is the sum of a-THF, b-THF and b-THE (the most abundant cortisol metabolites). While free cortisol is the best assessment for tissue levels of cortisol, it only represents 1-3% of the total produced. The total metabolized cortisol best represents the total glandular output for the day.

- **A potential preference for cortisol or cortisone (the inactive form):**

Looking at the comparison between the total for free cortisol and free cortisone is NOT the best indication of a person's preference for cortisol or cortisone. The saliva gland converts cortisol to cortisone in the local tissue. This localized conversion can be seen by comparing cortisol (free) and cortisone levels. To know how much free cortisol was made by the adrenals we must know how much was deactivated to free cortisone at the level of the saliva gland. **However, to determine total systemic preference of steroid activity, it is best to look at which metabolite predominates (THF or THE?).** This preference can be seen in the fan style gauge. This is known as the 11b-HSD index. The enzyme 11b-HSD II converts cortisol to cortisone in the kidneys, saliva gland and colon. 11b-HSD I is more active in the liver, fat cells and the periphery and is responsible for reactivating cortisone to cortisol. Both are then metabolized by 5a-reductase to become tetrahydrocortisol (THF) and tetrahydrocortisone (THE) respectively.

- **The Cortisol Awakening Response (CAR):**

The unique feature of the DUTCH Plus is the inclusion of the CAR assessment. The response to waking adds one more piece to HPA-axis function. In some cases, overall levels of free cortisol may be normal, but the response to stress may be under or overactive.

The Cortisol Awakening Response is measured as a percent difference between the waking and 30-minute (peak) cortisol. Additional information can be gathered by further measuring the percent difference between the waking and 60-minute (recovery) cortisol. This up and down pattern is thought to reflect the individual's natural response to stress, where the act of waking up serves as a mini "stress test".

In addition to the CAR, the overall total can be assessed by looking at the salivary cortisol total as well as the individual points.

Reasons for a lower CAR might include: an underactive HPA Axis, excessive psychological burnout, seasonal affective disorder (SAD), sleep apnea or poor sleep in general, PTSD, and "chronic fatigue" patients.

An elevated CAR can be a result of an over-reactive HPA axis, ongoing job-related stress (anticipatory stress for the day), glycemic dysregulation, pain (ie. waking with painful joints or a migraine), and general depression (not SAD). Scientific literature points to the magnitude of the morning cortisol increase as being connected to HPA-axis health whether the overall production of cortisol is low, normal or high.

**- The patient submitted an Insomnia salivary sample. The cortisol result for this sample was 1.65ng/mL. The cortisone result was 5.5 ng/mL. Ranges can be found in the table on the last page.**

### **Nutritional Organic Acids**

Organic acids are the metabolic byproducts of cellular activity in the body. Organic acid production varies by the individual and can be influenced by foods, environmental toxins, medications or supplements, nutrient status,

genetics and more. Organic acids begin to build up when a nutrient cofactor or mineral is not present for a specific reaction to occur. As a response, byproducts (organic acids) build up and can be measured in urine. On the DUTCH test, the organic acids we measure were chosen due to their specific roles in the metabolism and function of enzymes required for hormone and adrenal health and function. As industry standard dictates, the organic acids are measured from the waking sample.

### **Methylmalonate (MMA)**

Methylmalonic acid is a metabolic byproduct of the Citric Acid Cycle (Krebs cycle). Methylmalonic acid requires adenosylcobalamin for conversion to succinyl-CoA and onto ATP synthesis. If someone does not absorb enough B12 from their diet due to low B12-rich food consumption, low stomach acid, has an autoimmune disorder impacting Intrinsic Factor in the gut (required for B12 absorption), or has a MUT enzyme SNP (required for conversion of MMA to Succinyl CoA, dependent on adenosylcobalamin) then MMA will build up. Vitamin B12 is required for COMT activity (estrogen methylation, dopamine breakdown) and PNMT activity (the enzyme that takes norepinephrine to epinephrine), but is also critical for memory, energy production (ATP synthesis), gait and more. When MMA is high, consider supporting B12 through foods, digestive support or supplementation.

### **Xanthurenate & Kynurenate**

Xanthurenate and kynurenate are metabolic byproducts in the production of tryptophan to NAD in the liver. If either xanthurenate or kynurenate build up in the urine, it can indicate a need for vitamin B6. This need is amplified if BOTH markers are elevated, and often indicates a more severe deficiency of vitamin B6. Vitamin B6 is critical as a co-factor to over 100 important reactions that occur in the human body and is stored in the highest concentration in muscle tissue.

Tryptophan is converted to NAD by the liver and one of the steps in this pathway requires B6. When B6 is insufficient, xanthurenate is made instead. Xanthurenate can also bind to iron and create a complex that increases DNA oxidative damage resulting in higher 8-OHdG levels. If both the xanthurenate and 8OHdG levels are elevated, there is likely an antioxidant insufficiency.

Kynurenate may also become elevated when patients are B6 deficient because of a different, possibly less B6 dependent pathway. While there is always some tryptophan going down the kynurenine pathway towards NAD, and possibly xanthurenate, this process is up regulated by inflammation, estrogen and cortisol elevations. If levels of estrogen or cortisol are high, it may exacerbate kynurenic acid and increase the need for vitamin B6. As the Xanthurenate and Kynurenate pathways lead to biomarkers with other influence in the body, elevations in these markers may not always agree.

### **Pyroglutamate**

Pyroglutamate is an intermediate in glutathione recycling and production. Glutathione requires the amino acids cysteine, glycine and glutamate for production. If the body cannot convert pyroglutamate forward to glutathione, it will show up elevated in the urine. High pyroglutamate is an established marker for glutathione deficiency.

Remember that glutathione is one of the most potent antioxidants in the human body and is especially important in getting rid of toxins including the reactive quinone species formed by 4-OH-E1 and 4-OH-E2. This reactive species can damage DNA if not detoxified by either methylation or glutathione.

Some have reported that low pyroglutamate may also be indicative of a need for glutathione; however, this is not established in the scientific literature.

*Note: Pyroglutamate in the urine can also be elevated with Italian cheese consumption. Italian Cheeses (parmesan, etc.) may transiently increase pyroglutamate because they use a thermophilic lactobacilli to ripen the cheese- which our gut breaks down into pyroglutamate. This is not clinically significant and only reflects that they ate this style of cheese (if applicable).*

### **Neurotransmitter Metabolites**

Neurotransmitters are chemical signals produced by neurons in tissues throughout the body that act as chemical messengers that influence mood, cortisol, heart rate, appetite, muscle contraction, sleep and more. Measuring neurotransmitters directly is difficult because of their instability, and their direct urinary measurements are controversial with respect to how well they reflect the body's level of these neuro-hormones.

Each of the neurotransmitters assessed on the DUTCH test (dopamine, norepinephrine/epinephrine) can be assessed indirectly by measuring their urine metabolites (HVA and VMA respectively). While these metabolites are not a perfect reflection of what is going on in the brain, the scientific literature does affirm their use for a good representation of overall levels of these neurotransmitters in the body.

### **Homovanillate (HVA)**

Homovanillate (HVA) is the primary metabolite of dopamine, a brain and adrenal neurotransmitter that comes

from tyrosine (with BH4 and iron as co-factors). Dopamine goes on to create norepinephrine and epinephrine (adrenaline).

Low levels of dopamine are associated with depression, addictions, cravings, apathy, pleasure seeking behaviors, increased sleepiness, impulsivity, tremors, low motivation fatigue and low mood.

High levels of dopamine are associated with agitation, insomnia, mania, hyperactivity, hyper-focus, high stress, anxiety and addictions/cravings/pleasure seeking (to maintain high levels).

High HVA can be caused by the use of the following supplements, foods or medications within 72 hours of collecting urine samples: tyrosine, phenylalanine, mucuna, quercetin, bananas, avocados as well as parkinson's medications. If these are being used, the HVA on the DUTCH test may not accurately reflect circulating dopamine levels and should be disregarded.

### **Vanilmandelate (VMA)**

Vanilmandelate (VMA) is the primary metabolite of norepinephrine and epinephrine (adrenaline). The adrenal gland makes cortisol and DHEA (from the adrenal cortex) as well as norepinephrine and epinephrine (from the adrenal medulla). When adrenal hormone output is low, VMA levels may be low. If HVA levels are significantly higher than VMA, there may be a conversion problem from dopamine to norepinephrine. This case can be caused by a copper or vitamin C deficiency.

The enzymes COMT (methylation of catechols) and MAO are needed to make HVA and VMA from dopamine and norepinephrine respectively. If these enzymes are not working properly, HVA and/or VMA may be low in urine, when circulating levels of dopamine and/or norepinephrine/epinephrine may not be low.

Low levels of norepinephrine/epinephrine are associated with addictions, cravings, fatigue, low blood pressure, low muscle tone, intolerance to exercise, depression, and loss of alertness.

High levels of norepinephrine and epinephrine are associated with feelings of stress, aggression, violence, impatience, anxiety, panic, excess worry/hypervigilance, insomnia, paranoia, increasing tingling/burning, loss of memory, pain sensitivity, high blood pressure and heart palpitations.

### **Melatonin (measured as 6-OHMS)**

Melatonin is considered one of our sleep hormones. It is made predominately by the pineal gland in response to darkness and is stimulated by melanocyte stimulating hormone (MSH). A low MSH is associated with insomnia and an increased perception of pain. Mold exposure can inhibit MSH as well. The majority of our melatonin production comes from the pineal gland, but melatonin is also made in the gut, and to a lesser extent in the bone marrow, lymphocytes, epithelial cells and mast cells.

Please note that some foods contain small amounts of melatonin that are unlikely to increase circulating levels of melatonin, but may increase metabolites in urine due to first pass metabolism. The most significant of these foods are tomatoes, walnuts, strawberries and caffeinated coffee. These foods are thought to contribute to mildly elevated urinary melatonin. Extremely high urinary melatonin is seen when melatonin is supplemented directly. This is also due to first pass metabolism and is not an accurate reflection of circulating melatonin.

*The DUTCH test uses the waking (A) sample to test melatonin. The urine sample given on waking reflects overnight hormone production and metabolism. This sample can be used to assess melatonin throughout the night. When patients take a middle of the night urine sample, a large amount of data strongly suggests that the waking sample alone still correlates best to overnight melatonin production, so the waking sample is still used for the DUTCH melatonin result.*

### **8-OHdG (8-Hydroxy-2-deoxyguanosine)**

8-OHdG (8-Hydroxy-2-deoxyguanosine) is a marker for estimating DNA damage due to oxidative stress (from ROS creation). 8-OHdG is considered pro-mutagenic and is a biomarker for various cancer and degenerative disease initiation and promotion states. It can be increased by chronic inflammation, increased cell turnover, chronic stress, hypertension, hyperglycemia/pre-diabetes/diabetes, kidney disease, IBD, chronic skin conditions (psoriasis/eczema), depression, atherosclerosis, chronic liver disease, Parkinson's (increasing levels with worsening stages), Diabetic neuropathy, COPD, bladder cancer, or insomnia (to name a few). Studies have shown higher levels in patients with breast and prostate cancers. When levels are elevated it may be prudent to eliminate or reduce any causes and increase the consumption of antioxidant containing foods and/or supplements.



## Reference Range Determination (last updated 11.23.2021)

We aim to make the reference ranges for our DUTCH tests as clinically appropriate and useful as possible. This includes the testing of thousands of healthy individuals and combing through the data to exclude those that are not considered "healthy" or "normal" with respect to a particular hormone. As an example, we only use a premenopausal woman's data for estrogen range determination if the associated progesterone result is within the luteal range (days 19-21 when progesterone should be at its peak). We exclude women on birth control or with any conditions that may be related to estrogen production. Over time the database of results for reference ranges has grown quite large. This has allowed us to refine some of the ranges to optimize for clinical utility. The manner in which a metabolite's range is determined can be different depending on the nature of the metabolite. For example, it would not make clinical sense to tell a patient they are deficient in the carcinogenic estrogen metabolite, 4-OH-E1 therefore the lower range limit for this metabolite is set to zero for both men and women. Modestly elevated testosterone is associated with unwanted symptoms in women more so than in men, so the high range limit is set at the 80th percentile in women and the 90th percentile for men. Note: the 90th percentile is defined as a result higher than 90% (9 out of 10) of a healthy population.

Classic reference ranges for disease determination are usually calculated by determining the average value and adding and subtracting two standard deviations from the average, which defines 95% of the population as being "normal." When testing cortisol, for example, these types of two standard deviation ranges are effective for determining if a patient might have Addison's (very low cortisol) or Cushing's (very high cortisol) Disease. Our ranges are set more tightly to be optimally used for Functional Medicine practices.

Below you will find a description of the range for each test:

| Female Reference Ranges (Updated 11.23.2021)   |      |       |      |      |                              |      |       |      |      |
|--|------|-------|------|------|------------------------------|------|-------|------|------|
|  | Low% | High% | Low  | High |                              | Low% | High% | Low  | High |
| b-Pregnanediol   | 20%  | 90%   | 600  | 2000 | Saliva Cortisol Waking (W)   | 20%  | 90%   | 1.6  | 4.6  |
| a-Pregnanediol   | 20%  | 90%   | 200  | 740  | Saliva Cortisol (W+30 min.)  | 20%  | 90%   | 3.7  | 8.2  |
| Estrone (E1)   | 20%  | 80%   | 12   | 26   | Saliva Cortisol (W+60 min.)  | 20%  | 90%   | 2.3  | 5.3  |
| Estradiol (E2)   | 20%  | 80%   | 1.8  | 4.5  | Saliva Cortisol (Afternoon)  | 20%  | 90%   | 0.4  | 1.5  |
| Estriol (E3)   | 20%  | 80%   | 5    | 18   | Saliva Cortisol (Night)      | 0    | 95%   | 0    | 0.9  |
| 2-OH-E1  | 20%  | 80%   | 5.1  | 13.1 | Saliva Cortisol (2-3 am)     | 0    | 90%   | 0    | 0.9  |
| 4-OH-E1  | 0    | 80%   | 0    | 1.8  | Saliva Cortisone Waking (W)  | 20%  | 90%   | 6.8  | 14.5 |
| 16-OH-E1   | 20%  | 80%   | 0.7  | 2.6  | Saliva Cortisone (W+30 min.) | 20%  | 90%   | 12.4 | 19.4 |
| 2-Methoxy-E1   | 0    | 80%   | 0    | 0.7  | Saliva Cortisone (W+60 min.) | 20%  | 90%   | 9.4  | 15.3 |
| 2-OH-E2  | 0    | 80%   | 0    | 1.2  | Saliva Cortisone Afternoon   | 20%  | 90%   | 2    | 7.1  |
| 4-OH-E2  | 0    | 80%   | 0    | 0.5  | Saliva Cortisone Night       | 0    | 95%   | 0    | 4.8  |
| DHEA-S   | 20%  | 90%   | 20   | 750  | Saliva Cortisone (2-3 am)    | 0    | 95%   | 0    | 4.8  |
| Androsterone   | 20%  | 80%   | 200  | 1650 | Melatonin (6-OHMS)           | 20%  | 90%   | 10   | 85   |
| Etiocolanalone   | 20%  | 80%   | 200  | 1000 | 8-OHdG                       | 0    | 90%   | 0    | 5.2  |
| Testosterone   | 20%  | 80%   | 2.3  | 14   | Methylmalonate               | 0    | 90%   | 0    | 2.2  |
| 5a-DHT   | 0    | 80%   | 0    | 6.6  | Xanthurenate                 | 0    | 90%   | 0    | 1.4  |
| 5a-Androstenediol  | 20%  | 80%   | 6    | 30   | Kynurenate                   | 0    | 90%   | 0    | 7.3  |
| 5b-Androstenediol  | 20%  | 80%   | 20   | 75   | Pyroglutamate                | 10%  | 90%   | 32   | 60   |
| Epi-Testosterone   | 20%  | 80%   | 2.3  | 14   | Homovanillate                | 10%  | 95%   | 4    | 13   |
| a-THF  | 20%  | 90%   | 75   | 370  | Vanilmandelate               | 10%  | 95%   | 2.4  | 6.4  |
| b-THF  | 20%  | 90%   | 1050 | 2500 |                              |      |       |      |      |
| b-THE  | 20%  | 90%   | 1550 | 3800 |                              |      |       |      |      |
| % = population percentile: Example - a high limit of 90% means results higher than 90% of the women tested for the reference range will be designated as "high." |      |       |      |      | Calculated Values            |      |       |      |      |
|  |      |       |      |      | Total DHEA Production        | 20%  | 80%   | 500  | 3000 |
|  |      |       |      |      | Total Estrogens              | 20%  | 80%   | 35   | 70   |
|  |      |       |      |      | Metabolized Cortisol         | 20%  | 90%   | 2750 | 6500 |
|  |      |       |      |      | Saliva Cortisol Total        | 20%  | 90%   | 9.6  | 19.3 |
|  |      |       |      |      | Saliva Cortisone Total       | 20%  | 90%   | 36   | 55   |

## Provider Notes:



606685

Requisition Accession

2022-02-16

Gillies, Donna

N FORM

\*\*BOTH SIDES OF FORM MUST BE COMPLETED\*\*

Fill out with blue or black ink only


**dutchplus**  
 COMPLETE WITH CORTISOL AWAKENING RESPONSE

\*Provider Section - Completion Required for Testing\*

## ORDERING HEALTHCARE PROVIDER

 RN Labs Pty Ltd  
 18/93 Rivergate Place  
 Murarrie QLD 4172  
 AUSTRALIA

PATIENT INFORMATION

## REQUIRED

Patient Name (last, first) GILLIES DONNADate of Birth (MM/DD/YY) 18/09/1962Height 160 cm Weight 64 kg ☒ Female ☐ MaleEmail Address bdgillies@hotmail.comAddress 17 Lauren CircuitCity BRISBANE State QLD Zip 4017 Country AUSTRALIA

Day Phone

Cell Phone 04 215 25 872

Ethnicity (To Accommodate Ethnic Hormonal Differences)

☐ Pacific Islander ☐ Asian Descent ☐ African Descent ☒ European Descent

WOMEN

Menstrual Cycles

☒ None ☐ Regular ☐ Irregular

Have you had any ovaries removed?

☐ Yes ☒ No

If Yes, how many?

☐ One ☐ Two

First Day of Last Menses

(MM/DD/YY) NIAPregnant: ☐ Yes ☒ NoBirth Control: ☐ Yes ☒ No

If Yes, please specify \_\_\_\_\_

## SAMPLE COLLECTION DATE AND TIME

Did you wake up in the night and urinate before collecting sample #1? ☒ Yes ☐ No

## #1 | Waking - Saliva

Date 6/2/22 Time 7.50 ☒ AM ☐ PM

## #1 | Waking - Urine

Date 6/2/22 Time 7.50 ☒ AM ☐ PM

## #2 | +30 Min. After Waking - Saliva

Date 6/2/22 Time 8.20 ☒ AM ☐ PM

## #3 | +60 Min. After Waking - Saliva

Date 6/2/22 Time 8.50 ☒ AM ☐ PM

## #4 | 2-3hrs After Waking - Urine

Date 6/2/22 Time 1030 ☒ AM ☐ PM

## #5 | 4pm-5pm - Saliva

Date 6/2/22 Time 4.20 ☐ AM ☒ PM

## #5 | 4pm-5pm - Urine

Date 6/2/22 Time 4.20 ☐ AM ☒ PM

## #6 | 10pm-Midnight - Saliva

Date 6/2/22 Time 9.13 ☐ AM ☒ PM

## #6 | 10pm-Midnight - Urine

Date 6/2/22 Time 9.10 ☐ AM ☒ PM

## #7 | Overnight-Insomnia - Saliva

Date 6/2/22 Time 2.50 am ☒ AM ☐ PM

## LAB USE ONLY

 RECEIVED  
 FEB 15 2022

## HORMONE, SUPPLEMENT AND PRESCRIPTION INFORMATION

 Please complete the following information for any **progesterone, estrogens, DHEA, testosterone, pregnenolone, melatonin** or **cortisol** (cortef, hydrocortisone, etc.) you are taking. "Date Last Used" should be the last time you took the hormone before finishing the test.

 For Route of Administration (ROA) list one of the following: **1**=oral, **2**=sublingual (under the tongue, between cheek/gum), **3**=transdermal (skin) cream, **4**=transdermal (skin) gel, **5**=vaginal/labial creams/inserts, **6**=rectal mucosa, **7**=patch, **8**=pellet, **9**=injection, **10**=other

| Hormone      | Brand   | ROA (1-10) | Dose (mg) | Date Last Used | Times Per Day | Length of Use |
|--------------|---------|------------|-----------|----------------|---------------|---------------|
| Progesterone | Acpharm | 2          | 300mg     | 2/6/22         | 1             | 18 months     |
| Testosterone | Acpharm | 2          | 3mg       | 2/6/22         | 1             |               |
| Biest        | Acpharm | 2          | 4mg       | 2/6/22         | 1             |               |
|              |         |            |           |                |               |               |
|              |         |            |           |                |               |               |

☐ Not taking any listed hormones

## PLEASE INDICATE IF YOU ARE TAKING ANY OF THE FOLLOWING PRESCRIPTIONS:

- ☐ DIM / I-3-C ☐ Thyroid (T3, T4) ☐ Hydrocortisone Cream ☐ Steroid Inhaler ☐ Nasal Spray  
☐ Glucocorticoid (Prednisone, Dexamethsone, etc.) ☐ Creatine ☐ Diabetes Medications  
☐ Opioid (Narcotic) Pain Medications (hydrocodone, fentanyl, codeine, oxycodone, etc.)  
☐ Blood Pressure Medications ☐ 5-HTP ☐ Anti-Depressants/SSRIs \_\_\_\_\_ (type)

Taken as 1 troche



Please List any Current/Recent  
Medical Diagnosis Not Listed  
Elsewhere On This Form

GERD - hiatus hernia

|   | I do not suspect I have this        | I suspect I may have this           | I have been diagnosed with this     |                          |
|---|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| <b>DISEASE STATES</b>                         |                                     |                                     |                                     |                          |
| Addison's Disease                             | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Adrenal Insufficiency                         | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Chronic Fatigue                               | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Cushing's Disease                             | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| High Blood Pressure                           | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Hyperthyroidism (Overactive)                  | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Hypothyroidism (Underactive)                  | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Kidney Disease                                | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Type 2 Diabetes                               | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| Polycystic Ovary Syndrome                     | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                          |
| <b>FATIGUE</b>                                |                                     |                                     |                                     |                          |
| Please Rate Your Fatigue Level During The Day |                                     |                                     |                                     |                          |
| 0 = Never/None                                | 0                                   | 1                                   | 2                                   | 3                        |
| 1 = Sometimes/Mild                            |                                     |                                     |                                     |                          |
| 2 = Often/Moderate                            |                                     |                                     |                                     |                          |
| 3 = Always/Severe                             |                                     |                                     |                                     |                          |
| Morning Fatigue                               | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> |
| Afternoon Fatigue                             | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> |
| Evening Fatigue                               | <input type="checkbox"/>            | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/> |

PLEASE CIRCLE SYMPTOMS YOU ARE EXPERIENCING AND RATE THE OVERALL CATEGORY.

0 = Never/None 1 = Sometimes/Mild 2 = Often/Moderate 3 = Always/Severe

| Women               | 0  | 1                                   | 2                        | 3                                   | Men                      | 0                   | 1  | 2                                   | 3                        |                          |                          |
|---------------------|--|-------------------------------------|--------------------------|-------------------------------------|--------------------------|---------------------|--|-------------------------------------|--------------------------|--------------------------|--------------------------|
| Androgen Excess     | Loss of Scalp Hair, Increased Body or Facial Hair, Acne                      | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> | Androgen Excess     | Increased Sex Drive, Body, or Facial Hair, Aggressive Behavior, Acne     | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Androgen Deficiency | Vaginal Dryness, Decreased Sex Drive, Libido                                 | <input type="checkbox"/>            | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Androgen Deficiency | Decreased Libido, Erections, or Muscle Size, Increased Belly Fat, Apathy | <input type="checkbox"/>            | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Estrogen Excess     | Tender or Fibrocystic Breasts, Mood Swings, Uterine Fibroids, Heavy Bleeding | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> | Estrogen Excess     | Weight Gain (Breast or Hips), Prostate Problems                          | <input type="checkbox"/>            | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Estrogen Deficiency | Hot Flashes, Night Sweats, Vaginal Dryness                                   | <input type="checkbox"/>            | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> |                     |  |                                     |                          |                          |                          |

| ADDITIONAL SYMPTOMS    | 0                                   | 1                                   | 2                                   | 3                        |
|------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| 0 = Never/None         |                                     |                                     |                                     |                          |
| 1 = Sometimes/Mild     |                                     |                                     |                                     |                          |
| 2 = Often/Moderate     |                                     |                                     |                                     |                          |
| 3 = Always/Severe      |                                     |                                     |                                     |                          |
| Trouble Falling Asleep | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> |
| Trouble Staying Asleep | <input type="checkbox"/>            | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| Depression             | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/> |
| Anxiety                | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/> |
| Migraines              | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/> |

WHICH BEST DESCRIBES YOU?

☐ Underweight  
☐ At ideal weight  
☒ 5-20 lbs Overweight  
☐ >20 lbs Overweight

Are you struggling to lose weight? ☒ Yes ☐ No

WHAT ARE THE TOP ISSUES YOU HOPE THIS TEST WILL HELP YOU RESOLVE?

- Why can't I lose weight
- Why do I wake early hrs ie 2-4am + can't go back to sleep
- Vaginal dryness + ↓ libido
- Why do I sleep 5-6 hrs/night - despite being tired

PLEASE LIST ANY ADDITIONAL MEDICATIONS OR SUPPLEMENTS YOU ARE CURRENTLY TAKING.

- Zoton - PPI for reflux
- Vitamin B12 SL - 1000mcg
- Magnesium nocte 800mg (x2)
- Kumeric - 30,000+ 1day
- Caltrate 25mcg
- Maltofer - 100mg Fe deficiency (2 months)

Patient notes — please list anything about your sample collection or medical situation that you feel may be important for this lab test.

Awoke 2:50am day of test  
 Couldn't go back to sleep until around 4:30-5am. Then slept  
 until I woke  
 + did my 1st test  
 at 7:50am.

\*\*\*BOTH SIDES MUST BE COMPLETED\*\*\*